Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,544
archived clinical trials in
Ovarian Cancer

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2 -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2 -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Click here to add this to my saved trials
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2 -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2 -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2 -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Cancer Institute (UPCI)
mi
from
Pittsburgh, PA
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2 -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Cancer Institute (UPCI)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2 -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2 -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Adrenal Hyperplasia Among Young People With PCOS
Adrenal Hyperplasia Among Young Patients With Polycystic Ovarian Syndrome
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Adrenal Hyperplasia Among Young People With PCOS
Adrenal Hyperplasia Among Young Patients With Polycystic Ovarian Syndrome
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase I/II Randomized Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase I/II Randomized Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Trial of Adjuvant FANG™ Vaccine for High Risk Stage III/IV Ovarian Cancer
Open Label Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Care Northwest
mi
from
Spokane, WA
Trial of Adjuvant FANG™ Vaccine for High Risk Stage III/IV Ovarian Cancer
Open Label Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Care Northwest
mi
from
Spokane, WA
Click here to add this to my saved trials
Trial of Adjuvant FANG™ Vaccine for High Risk Stage III/IV Ovarian Cancer
Open Label Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center
mi
from
Lebanon, NH
Trial of Adjuvant FANG™ Vaccine for High Risk Stage III/IV Ovarian Cancer
Open Label Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Trial of Adjuvant FANG™ Vaccine for High Risk Stage III/IV Ovarian Cancer
Open Label Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists
mi
from
West Palm Beach, FL
Trial of Adjuvant FANG™ Vaccine for High Risk Stage III/IV Ovarian Cancer
Open Label Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Trial of Adjuvant FANG™ Vaccine for High Risk Stage III/IV Ovarian Cancer
Open Label Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer
Status: Enrolling
Updated:  12/31/1969
Mary Crowley Cancer Research Centers
mi
from
Dallas, TX
Trial of Adjuvant FANG™ Vaccine for High Risk Stage III/IV Ovarian Cancer
Open Label Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer
Status: Enrolling
Updated: 12/31/1969
Mary Crowley Cancer Research Centers
mi
from
Dallas, TX
Click here to add this to my saved trials
Trial of Adjuvant FANG™ Vaccine for High Risk Stage III/IV Ovarian Cancer
Open Label Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Oncology - Fort Worth
mi
from
Fort Worth, TX
Trial of Adjuvant FANG™ Vaccine for High Risk Stage III/IV Ovarian Cancer
Open Label Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Oncology - Fort Worth
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Trial of Adjuvant FANG™ Vaccine for High Risk Stage III/IV Ovarian Cancer
Open Label Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Oncology Sammons Cancer Center
mi
from
Dallas, TX
Trial of Adjuvant FANG™ Vaccine for High Risk Stage III/IV Ovarian Cancer
Open Label Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Oncology Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Michigan Health System
mi
from
Ann Arbor, MI
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Scottsdale Healthcare
mi
from
Scottsdale, AZ
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Scottsdale Healthcare
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Virginia G. Piper Cancer Center Research Pharmacy
mi
from
Scottsdale, AZ
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Virginia G. Piper Cancer Center Research Pharmacy
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated:  12/31/1969
(IRB# 12-000131) Ronald Reagan UCLA Medical Center, Drug Information Center
mi
from
Los Angeles, CA
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated: 12/31/1969
(IRB# 12-000131) Ronald Reagan UCLA Medical Center, Drug Information Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Ronald Reagan UCLA Medical Center
mi
from
Los Angeles, CA
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Ronald Reagan UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Ucla Hematology/Oncology
mi
from
Los Angeles, CA
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Ucla Hematology/Oncology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Westwood Bowyer Clinic, Peter Morton Medical Building
mi
from
Los Angeles, CA
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Westwood Bowyer Clinic, Peter Morton Medical Building
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Santa Monica/UCLA Medical Center and Orthopaedic Hospital
mi
from
Santa Monica, CA
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Santa Monica/UCLA Medical Center and Orthopaedic Hospital
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated:  12/31/1969
UCLA Hematology-Oncology Santa Monica
mi
from
Santa Monica, CA
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated: 12/31/1969
UCLA Hematology-Oncology Santa Monica
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated:  12/31/1969
IU Health Bloomington Hospital
mi
from
Bloomington, IN
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated: 12/31/1969
IU Health Bloomington Hospital
mi
from
Bloomington, IN
Click here to add this to my saved trials
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Indiana University Health Melvin And Bren Simon Cancer Center
mi
from
Indianapolis, IN
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Indiana University Health Melvin And Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Investigational Drug Services
mi
from
Indianapolis, IN
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Investigational Drug Services
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated:  12/31/1969
IU Health University Hospital
mi
from
Indianapolis, IN
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated: 12/31/1969
IU Health University Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Royal Marsden Hospital NHS Foundation Trust
mi
from
Sutton,
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Royal Marsden Hospital NHS Foundation Trust
mi
from
Sutton,
Click here to add this to my saved trials
Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
PHASE I STUDY OF CARBOPLATIN, PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) AND EVEROLIMUS IN PATIENTS WITH PLATINUM-SENSITIVE EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER IN FIRST RELAPSE
Status: Enrolling
Updated:  12/31/1969
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
PHASE I STUDY OF CARBOPLATIN, PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) AND EVEROLIMUS IN PATIENTS WITH PLATINUM-SENSITIVE EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER IN FIRST RELAPSE
Status: Enrolling
Updated: 12/31/1969
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated:  12/31/1969
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated: 12/31/1969
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated:  12/31/1969
Connecticut Children's Medical Center
mi
from
Hartford, CT
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated: 12/31/1969
Connecticut Children's Medical Center
mi
from
Hartford, CT
Click here to add this to my saved trials
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated:  12/31/1969
Saint Jude Midwest Affiliate
mi
from
Peoria, IL
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated: 12/31/1969
Saint Jude Midwest Affiliate
mi
from
Peoria, IL
Click here to add this to my saved trials
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated:  12/31/1969
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated: 12/31/1969
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated:  12/31/1969
Children's Mercy Hospital
mi
from
Kansas City, MO
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated: 12/31/1969
Children's Mercy Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated:  12/31/1969
Rainbow Babies and Children's Hospital
mi
from
Cleveland, OH
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated: 12/31/1969
Rainbow Babies and Children's Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated:  12/31/1969
BI-LO Charities Children's Cancer Center
mi
from
Greenville, SC
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated: 12/31/1969
BI-LO Charities Children's Cancer Center
mi
from
Greenville, SC
Click here to add this to my saved trials
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated:  12/31/1969
East Tennessee Children's Hospital
mi
from
Knoxville, TN
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated: 12/31/1969
East Tennessee Children's Hospital
mi
from
Knoxville, TN
Click here to add this to my saved trials
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated:  12/31/1969
Driscoll Children's Hospital
mi
from
Corpus Christi, TX
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated: 12/31/1969
Driscoll Children's Hospital
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated:  12/31/1969
Covenant Children's Hospital
mi
from
Lubbock, TX
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated: 12/31/1969
Covenant Children's Hospital
mi
from
Lubbock, TX
Click here to add this to my saved trials
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated:  12/31/1969
Methodist Children's Hospital of South Texas
mi
from
San Antonio, TX
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated: 12/31/1969
Methodist Children's Hospital of South Texas
mi
from
San Antonio, TX
Click here to add this to my saved trials
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Alabama
mi
from
Birmingham, AL
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham Cancer Center
mi
from
Birmingham, AL
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated:  12/31/1969
Arkansas Children's Hospital
mi
from
Little Rock, AR
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated: 12/31/1969
Arkansas Children's Hospital
mi
from
Little Rock, AR
Click here to add this to my saved trials
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated:  12/31/1969
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated: 12/31/1969
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Downey Medical Center
mi
from
Downey, CA
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Downey Medical Center
mi
from
Downey, CA
Click here to add this to my saved trials
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated:  12/31/1969
Miller Children's and Women's Hospital Long Beach
mi
from
Long Beach, CA
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated: 12/31/1969
Miller Children's and Women's Hospital Long Beach
mi
from
Long Beach, CA
Click here to add this to my saved trials
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated:  12/31/1969
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated: 12/31/1969
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated:  12/31/1969
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated: 12/31/1969
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
mi
from
Denver, CO
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated:  12/31/1969
Lee Memorial Health System
mi
from
Fort Myers, FL
Collecting and Storing Tissue From Young Patients With Cancer
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Status: Enrolling
Updated: 12/31/1969
Lee Memorial Health System
mi
from
Fort Myers, FL
Click here to add this to my saved trials